» Articles » PMID: 35929960

Nanotechnology-Inspired Extracellular Vesicles Theranostics for Diagnosis and Therapy of Central Nervous System Diseases

Overview
Date 2022 Aug 5
PMID 35929960
Authors
Affiliations
Soon will be listed here.
Abstract

Shuttling various bioactive substances across the blood-brain barrier (BBB) bidirectionally, extracellular vesicles (EVs) have been opening new frontiers for the diagnosis and therapy of central nervous system (CNS) diseases. However, clinical translation of EV-based theranostics remains challenging due to difficulties in effective EV engineering for superior imaging/therapeutic potential, ultrasensitive EV detection for small sample volume, as well as scale-up and standardized EV production. In the past decade, continuous advancement in nanotechnology provided extensive concepts and strategies for EV engineering and analysis, which inspired the application of EVs for CNS diseases. Here we will review the existing types of EV-nanomaterial hybrid systems with improved diagnostic and therapeutic efficacy for CNS diseases. A summary of recent progress in the incorporation of nanomaterials and nanostructures in EV production, separation, and analysis will also be provided. Moreover, the convergence between nanotechnology and microfluidics for integrated EV engineering and liquid biopsy of CNS diseases will be discussed.

Citing Articles

The simultaneous use of nanovesicles and magnetic nanoparticles for cancer targeting and imaging.

Salatin S, Azarfarin M, Farjami A, Hamidi S Ther Deliv. 2024; 16(2):167-181.

PMID: 39564978 PMC: 11849928. DOI: 10.1080/20415990.2024.2426447.


Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions.

Choi H, Chen M, Goldston L, Lee K Nano Converg. 2024; 11(1):19.

PMID: 38739358 PMC: 11091041. DOI: 10.1186/s40580-024-00426-5.


Tissue Engineering in Neuroscience: Applications and Perspectives.

Zhang X, Liu F, Gu Z BME Front. 2023; 4:0007.

PMID: 37849680 PMC: 10521717. DOI: 10.34133/bmef.0007.


Catalpol inhibits hepatic stellate cell activation by reducing the formation and changing the contents of hepatocyte-derived extracellular vesicles.

Xie Z, Cao H, Wang Q, Lu H, Du W J Cell Commun Signal. 2022; 17(3):723-736.

PMID: 36508052 PMC: 10409968. DOI: 10.1007/s12079-022-00716-9.